

Microbicide Trials Network

CLARIFICATION MEMO #03 TO:

MTN-034

A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

DAIDS Protocol #: 12066

IND#: 139,598

Version 2.0 / 7 December 2017

Clarification Memo Date: 30 March 2021

Section 1: Summary of Clarifications and Rationale

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB/IEC approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB/IEC overseeing the study at their site for information. This CM is official MTN-034 documentation and is effective immediately. A copy of this CM must be retained in each study site's Essential Documents file for MTN-034. No change in informed consent is necessitated by or included in this CM.

This document expands Section 12 site monitoring language to allow remote site monitoring, per recent DAIDS guidance, and updates the references in Sections 11 and 13 to the DAIDS Site Clinical Operations and Research Essentials (SCORE) Manual, also per recent DAIDS guidance. This document also updates the Truvada tablet package insert version and the protocol team roster.

Section 2: Implementation

With the exception of updates to the protocol team roster, text to be deleted is noted below with a ~~strike through~~, text to be added is in **bold**, and text in **bold italics** is not to be added, but to serve as a clarification of the implementation item in question. This information will be included in the protocol the next time the protocol is updated.

The following revisions allow remote site monitoring per recent DAIDS guidance:

- 1.) Second sentence of the first paragraph in Section 12, *Clinical Site Monitoring*:

Study monitors will ~~visit study sites to do the following~~:

- 2.) First sentence of the second paragraph in Section 12, *Clinical Site Monitoring*:

Monitoring visits may be conducted on-site or remotely. Remote visits may include remote source document verification using methods specified for this purpose by NIAID. Remote monitoring visits may be performed in place of or in addition to onsite visits to ensure the safety of study participants and data integrity. The site will make available study documents for site monitors to review utilizing a secure platform. Selected platforms must be confirmed with the DAIDS Office of Clinical Site Oversight (OCSO) in advance.

For on-site visits, the ~~The~~ **IoRs/designees will allow study monitors to inspect study facilities and documentation (e.g., informed consent forms, clinic and laboratory records, other source documents, CRFs), as well as observe the performance of study procedures.**

The following revisions update the reference to DAIDS' SCORE Manual per recent DAIDS guidance:

- 3.) First sentence of the first paragraph in Section 11.2, *Source Documents and Access to Source Data/Documents*:

All study sites will maintain source data/documents in accordance with **the DAIDS Site Clinical Operations and Research Essentials (SCORE) Manual** (<https://www.niaid.nih.gov/research/daids-score-manual>) ~~Requirements for Source Documentation in DAIDS Funded and/or Sponsored Clinical Trials~~ (<https://www.niaid.nih.gov/sites/default/files/daids-sourcedocpolicy.pdf>) and the relevant appendix regarding source documentation (<https://www.niaid.nih.gov/sites/default/files/sourcedocappndx.pdf>).
- 4.) First sentence of the first paragraph in Section 11.3, *Quality Control and Quality Assurance*:

All study sites will conduct quality control and quality assurance procedures in accordance with **the DAIDS SCORE Manual** (<https://www.niaid.nih.gov/research/daids-score-manual>) ~~Requirements for Clinical Quality Management Plans at DAIDS Funded and/or Supported Clinical Research Sites~~ (<https://www.niaid.nih.gov/sites/default/files/qmppolicy.pdf>).
- 5.) Fourth sentence of the first paragraph in Section 13.5, *Informed Consent Process*:

Study staff must document the informed consent process in accordance with the **DAIDS SCORE Manual** (<https://www.niaid.nih.gov/research/daids-score-manual>) ~~Requirements for Source Documentation in DAIDS Funded and/or Sponsored Clinical Trials~~ (<https://www.niaid.nih.gov/sites/default/files/daids-sourcedocpolicy.pdf>).
- 6.) Protocol references to the Truvada Package Insert were updated to the most current version dated June 2020.
- 7.) Protocol Team Roster – Deletions: Jared Baeten, Kim Woodhouse, Shakeera Arnolds, Shorai Mukaka.
- 8.) Protocol Team Roster – Updates:

Gonasagrie Nair, MBChB, MPH
Protocol Chair
~~Emavundloni Research Centre~~
14 Senwabile Drive
Crossroads 7750
Stellenbosch University, Centre for Medical Ethics and Law
Cape Town South Africa
Phone: ~~27-21-650-5873~~ **27-021-938-9600**
Email: ~~lulu.nair@hiv-research.org.za~~ **gnair@sun.ac.za**

Z. Mike Chirenje MD, FRCOG
CTU PI
UZCHS CTRC
15 Phillips Avenue, Belgravia
Harare, Zimbabwe
Phone: 263-4-704-966
Fax: 263-4-704-897
Email: ~~mchirenje@uzchs-ctu.org~~ **mchirenje@uz-ctrc.org**

Naana Cleland, MHCA
Health Specialist, Clinical Microbicide Research Branch (CMRB)
~~Prevention Sciences Program (PSP)~~ **Therapeutics Research Program (TRP)** DAIDS, NIAID
NIH - U.S. Department of Health and Human Services (HHS)
5601 Fishers Lane, Room 8B27
Rockville, MD 20852 USA
Phone: 240-292-4779
Email: clelandn@niaid.nih.gov

Ariane van der Straten, PhD, MPH
~~QDMC Director and BRWG Co-representative~~
~~Women's Global Health Imperative Program~~

RTI International
351 California Street, Suite 500
San Francisco, CA 94104 USA
Phone: 415-848-1324
Fax: 415-848-1330
Email: ariane@rti.org

Microbicide Trials Network
256 Stanford Avenue
Kensington, CA 94708
Phone: 510-374-9187
Email: arianevds@gmail.com

Charles Chasakara
CWG Representative
~~UZ-UCSF Research Programme~~ **UZ CTRC**
10 Routeledge Road Milton Park
Harare, Zimbabwe
Phone: 263-4-291-5421
Fax: 263-4-704-897
Email: cchasakara@uz-ucsf.co.zw cchasakara@uz-ctrc.org

Sarah T. Roberts, PhD
QDMC Project Director and Research Analyst
Women's Global Health Imperative Program
RTI International
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA
Phone: 415-848-1335
Email: sroberts@rti.org

Mary Kate Shapley-Quinn, MPH
~~Project Coordinator and Data~~ **QDMC Project Manager**
Women's Global Health Imperative Program
RTI International
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA
Phone: 415-848-1316
Email: mshapley@rti.org

9.) Protocol Team Roster – Additions:

Philippa Macdonald, MBChB, MRCP
Site Investigator of Record
Emavundleni Research Centre
14 Sonwabile Drive
Old Crossroads
Klipfontein 7750
Cape Town South Africa
Phone: 27-021-650-5848
Email: Pippa.Macdonald@hiv-research.org.za

Bekezela Siziba, MBChB, MPH
Site Investigator of Record
UZ CTRC
15 Phillips Avenue, Belgravia
Harare, Zimbabwe
Phone: 263-77-267-0810
Fax: 263-4-704-897
Email: bsiziba@uz-ctrc.org

Jontraye Davis, MHA
Community Program Manager
FHI 360
359 Blackwell St., Suite 200
Durham, NC 27701 USA
Phone: 919-544-7040, Ext. 11715
Fax: 919-544-0904
Email: jodavis@fhi360.org

Alinda Young, MPH
Qualitative Project Coordinator
Women's Global Health Imperative Program
RTI International
2150 Shattuck Avenue, Suite 800
Berkeley, CA 94704 USA
Phone: 510-518-7016
Email: amyyoung@rti.org

The above information will be incorporated into the next version of the protocol at a later time if it is amended.